November 8, 2022

Cameron Ball, PhD
Chief Executive Officer
Uh-Oh Labs Inc.
3485 Victor St
Santa Clara, CA 95054

Re: EUA210666/S002 & S006
Trade/Device Name: UOL COVID-19 Test
Dated: June 17, 2022 & September 22, 2022
Received: June 17, 2022 & September 22, 2022

Dear Dr. Ball:

This is to notify you that your request to update the UOL COVID-19 Test to; (1) add a new qualified supplier of test oligonucleotides, and (2) abbreviate the name of the "Uh-Oh Labs Dx Pro" Mobile Application (App) to "Dx Pro" for the purposes of the App display icon, is granted. Upon review, we concur that the data and information submitted in EUA210666/S002 & S006 supports the requested updates for use with the UOL COVID-19 Test. By submitting this EUA revision for review by the Food and Drug Administration (FDA), you have complied with the Conditions of Authorization stated in the letter authorizing the emergency use of the UOL COVID-19 Test issued on February 8, 2022.

Sincerely yours,

_____

Uwe Scherf, M.Sc., Ph.D.
Director, Division of Microbiology Devices
OHT7: Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health